PHARM

INTERMEDIATE

Why Choose PHILCHEM?

“The most reliable global sourcing solution, from early-stage R&D to commercial mass production.”

As competition in new drug R&D and alternative process development, the rapid procurement of high-purity intermediates and fine reagents has become a core competitive advantage for pharmaceutical companies. Based on over 20 years of accumulated expertise in fine chemicals and raw material imports, PHILCHEM directly connects verified top-tier global manufacturers with domestic pharmaceutical companies.

Going beyond simple raw material distribution, we perfectly meet the stringent impurity profile requirements of our clients’ research institutes and guarantee a seamless supply chain—from small lab-scale samples to ton-scale commercial supply. PHILCHEM is your most reliable and trusted partner in shortening synthesis processes and realizing cost reductions.

[Top 20 Core Intermediate Portfolios Optimized for the Synthesis and CDMO Market]

Category Intermediate Name Target Drug & Trend Key Sourcing Point
Peptides & Obesity/Diabetes SNAC (Salcaprozate Sodium) Oral GLP-1 (e.g., Semaglutide) An essential absorption enhancer for oralizing obesity drug pipelines; the #1 priority for R&D departments.
GLP-1 Side Chains Long-acting peptide obesity treatments Lipid side chains that maintain peptide efficacy; demand is surging due to large-scale production expansions.
CTC Resin / Wang Resin Solid-phase peptide synthesis (SPPS) Essential resins for peptide synthesis; directly impacts yield, making it crucial to secure high-quality vendors.
HATU, COMU Peptide and amino acid coupling Premium coupling reagents with overwhelmingly high yields, essential for complex new drug synthesis.
Next-Gen Modalities (ADC & RNA) ADC Linkers (e.g., Mc-Vc-PAB) Antibody-Drug Conjugate (ADC) anti-cancer drugs High-value linker materials in the ADC sector, which companies are rushing into to secure global CDMO contracts.
Phosphoramidites Oligonucleotides (siRNA, mRNA) Core building blocks in the RNA-based raw material market.
Ionizable Lipids / PEG Lipids LNP (Lipid Nanoparticle) delivery systems Ultra-high-cost lipid materials acting as capsules to deliver mRNA vaccines and treatments into the body.
Domestic Blockbuster New Drugs Tegoprazan Intermediate P-CAB Gastrointestinal Drug (K-CAB) An essential target for developing generics and incrementally modified drugs for domestic blockbusters with overwhelming prescription sales.
Fexuprazan Intermediate P-CAB Gastrointestinal Drug (Fexuclue) High demand for ultra-precision synthesis at the research level to bypass patents of leading P-CAB products.
Oncology & Highly Difficult Chiral Osimertinib Intermediate NSCLC Targeted Therapy (Tagrisso) A highly profitable oncology API with massive demand for high-purity intermediates that can shorten the process.
Deruxtecan Intermediate Next-Gen Breast/Gastric Cancer ADC (Enhertu) The core payload (toxic drug) intermediate of the product leading the global anti-cancer market.
Sacubitril Chiral Intermediate Chronic Heart Failure (Entresto) An essential chiral material for generic development; discovering vendors that guarantee high optical purity is the key to success.
Palbociclib Intermediate Breast Cancer Targeted Therapy (Ibrance) A pyridopyrimidine structure material preferred by factories aiming to maximize added value through in-house synthesis.
Enzalutamide Intermediate Prostate Cancer Treatment (Xtandi) A high-cost material optimized for pharmaceutical companies seeking to reduce API import costs and promote in-house synthesis.
Sterile & High-Quality Antibiotics Cephalosporin Side Chains Cephalosporin & Carbapenem Antibiotics Constant sourcing of low-cost, high-quality side chains is required to maintain export competitiveness of finished products.
Tazobactam Intermediate Beta-Lactamase Inhibitor Combination Antibiotics A steady demand item at the ton scale for dedicated factories synthesizing high-purity sterile injectable antibiotics.
General & Fine Reagents Chiral Resolving Agents Optical Isomer Separation Premium reagents used to isolate only the necessary isomers, becoming mandatory due to tightening quality regulations.
Boc-Anhydride Amine Protecting Reagent A consumable used by the ton in almost all API synthesis plants, ensuring a solid base cargo volume.
Silica Gel (Chromatography) High-Purity API Purification Consumption of large-scale purification silica gel has skyrocketed due to stricter API purification standards.
Metal Catalysts Precious Metal Catalytic Reactions (e.g., Palladium) High-priced metal catalysts essential for modern pharmaceutical synthesis, such as Suzuki coupling.

Why Pharmaceutical Companies Must Pay Attention to These Core Intermediates

“The Key to Securing Global CDMO Competitiveness and Successful High-Value R&D”

  1. Preempting the Next-Generation Modality Market: The market for next-generation treatments like peptides (obesity/diabetes) and ADCs (oncology) is expanding exponentially. This portfolio goes beyond simple generic competition, serving as an essential core weapon for pharmaceutical companies diving into high-value new drug R&D and global CDMO bidding wars.
  2. Responding to the Mega-Blockbuster Patent Cliff: The patent expirations of blockbuster drugs generating massive sales—such as Entresto, Tagrisso, and K-CAB—are imminent. Preemptively securing high-purity intermediates to support alternative process development and precise chiral synthesis will determine the success of market preemption.
  3. Breaking Through Regulatory Barriers and Accelerating R&D: Instead of going through the rigorous finished API registration (KDMF) process, importing high-quality intermediates and conducting the final processes domestically can dramatically accelerate a pharmaceutical company’s R&D speed and commercialization schedule.
  4. Overwhelming Cost Competitiveness and Impurity Control: Through a strong direct-deal network with leading global fine chemical vendors in India, China, and elsewhere, we supply high-quality materials with perfectly controlled impurities (such as NDMA) at the most economical unit prices, thereby maximizing your final operating profit margins.